Skip to content
Homepage
Author:
Tris Pharma, Inc.
Posted Date:
June 11, 2026
Tris Pharma to Present on Dual NOP/MOP Receptor Agonist in Pain Management and Substance Use Disorder at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, 2026
Tris Pharma, Inc.
June 11, 2026
Tris Pharma Announces FDA Grant of Orphan Drug Designation for TRN-257 (Oxybate for Extended-Release Oral Suspension) a Once-Nightly, Low-Sodium Oxybate Product for Idiopathic Hypersomnia
Tris Pharma, Inc.
June 10, 2026
Tris Pharma Introduces a New 60 mL Bottle Size for DYANAVEL® XR (amphetamine) Extended-Release Oral Suspension CII
Tris Pharma, Inc.
June 8, 2026
Tris Pharma Announces Presentation on The Complexity and Management of ADHD at Psych Congress Elevate 2026
Tris Pharma, Inc.
June 2, 2026
Tris Pharma Appoints Jim Potenziano, Ph.D. as Chief Science and Development Officer
Tris Pharma, Inc.
May 5, 2026
Tris Pharma to Showcase Encore Phase 3 Data Supporting Continued Progress in Acute Pain Treatment at ASRA 2026 Meeting in Phoenix
Tris Pharma, Inc.
April 8, 2026
Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting
Tris Pharma, Inc.
March 6, 2026
